药物性肝损伤筛查干预的经济学评价
该研究用马尔可夫模型模拟中低收入国家HIV与TB共感染患者接受抗逆转录病毒治疗和抗结核治疗时的肝功监测,比较纸基即时检测与金标准实验室检测相对临床监测的成本效果。纸基检测较单纯临床监测效果提高56%,且每检测成本上限为1.60美元时比金标准更具成本效果。
要点
- 纸基即时检测较单纯临床监测效果提高56%
- 纸基ALT筛查每检测成本上限为1.60美元时具成本效果
- 金标准监测在LMIC不可及时纸基检测有潜在价值
核心结论
- 纸基即时肝功检测在中低收入国家HIV与TB共感染患者中较金标准更具成本效果,成本上限为每检测1.60美元。
研究设计与样本
- 采用马尔可夫模型模拟中低收入国家HIV与TB共感染患者诊疗,数据来自公开数据及布隆迪Village Health Works。
主要发现
- 纸基检测较单纯临床监测效果提高56%。
- 纸基检测在金标准方法不可实现时具有成本效果优势。
关键数值与推荐
- 纸基检测成本上限为每检测1.60美元。
- 比较对象为纸基即时检测、金标准实验室检测与基线临床监测。
临床怎么用
- 政策制定者可据此评估纸基检测在金标准监测不可及地区的价值。
- 研发时应将ALT筛查检测成本控制在1.60美元以内。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human immunodeficiency virus (HIV)/AIDS and tuberculosis (TB) continue to be a significant global burden, disproportionately affecting low- and middle-income countries (LMICs). While much progress has been made in treating these epidemics, this has led to a rise in liver complications, as patients on ARTs and anti-TBs are at an increased risk of drug-induced liver injury (DILI). Therefore, patients on these medicines require consistent screening of liver function. Due to logistical barriers, gold standard DILI screening fails to be executed at the point-of-care in LMICs. For this reason, we used cost-effectiveness analysis to gauge the efficacy of a paper-test that could be implemented in these settings. METHODS: We used a Markov Model to simulate HIV and TB coinfected patient care in LMICs using both publicly available data and data from Village Health Works in Burundi. We compared the cost-effectiveness of two screening interventions for liver function monitoring: 1. paper-based point-of-care testing, and 2. gold-standard laboratory testing. These interventions were compared against baseline clinical monitoring. RESULTS: The paper test showed a 56% increase in efficacy over clinical monitoring alone. The paper-test is more cost-effective than the gold-standard method, at a ceiling cost of $1.60 per test. CONCLUSIONS: With this information, policy makers can be informed as to the large potential value of paper-based tests when gold standard monitoring is not achievable. Scientists and engineers should also keep these analyses in mind and while in development limit the cost of an ALT screening test to $1.60.
引用
- Moed S, Suprenant M, Odjidja EN, et al. Economic Evaluation of Screening Interventions for Drug-induced Liver Injury. Clin Infect Dis. 2021. PMID: 32898262. doi:10.1093/cid/ciaa1347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。